Vimarsana
Biggest News Aggregation in the World

18946410 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 18946410. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 18946410 Today - Breaking & Trending Today

Clovis Oncology (NASDAQ:CLVS) Expected to Announce Quarterly Sales of $37.26 Million - Vimarsana News

Clovis Oncology (NASDAQ:CLVS) Expected to Announce Quarterly Sales of $37.26 Million

Analysts forecast that Clovis Oncology (NASDAQ:CLVS – Get Rating) will announce sales of $37.26 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Clovis Oncology’s earnings, with the highest sales estimate coming in at $39.43 million and the lowest estimate coming in at $35.08 million. Clovis Oncology posted sales of […]

Clovis Oncology (NASDAQ:CLVS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - Vimarsana News

Clovis Oncology (NASDAQ:CLVS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Clovis Oncology (NASDAQ:CLVS – Get Rating) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01), MarketWatch Earnings reports. During the same quarter last year, the firm posted ($0.64) EPS. Shares of NASDAQ:CLVS traded down $0.48 on Friday, reaching $0.99. […]

Reviewing Clovis Oncology (NASDAQ:CLVS) and Kronos Bio (NASDAQ:KRON) - Vimarsana News

Reviewing Clovis Oncology (NASDAQ:CLVS) and Kronos Bio (NASDAQ:KRON)

Clovis Oncology (NASDAQ:CLVS – Get Rating) and Kronos Bio (NASDAQ:KRON – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk. Earnings & Valuation This table compares Clovis Oncology and […]

Clovis Oncology Sees Unusually High Options Volume (NASDAQ:CLVS) - Vimarsana News

Clovis Oncology Sees Unusually High Options Volume (NASDAQ:CLVS)

Clovis Oncology (NASDAQ:CLVS – Get Rating) saw unusually large options trading on Thursday. Stock investors bought 106,147 call options on the stock. This is an increase of 2,981% compared to the average volume of 3,445 call options. Several equities research analysts have recently issued reports on the stock. StockNews.com initiated coverage on shares of Clovis […]

$37.03 Million in Sales Expected for Clovis Oncology (NASDAQ:CLVS) This Quarter - Vimarsana News

$37.03 Million in Sales Expected for Clovis Oncology (NASDAQ:CLVS) This Quarter

Equities analysts predict that Clovis Oncology (NASDAQ:CLVS – Get Rating) will report $37.03 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Clovis Oncology’s earnings. The highest sales estimate is $37.04 million and the lowest is $37.02 million. Clovis Oncology reported sales of $38.05 million during […]